Tag Archives: personalized medicine

Circulating Biomarkers Dundee 2014 a Success!

Circulating Biomarkers Dundee 2014 was a great success! The leadership of Ed Quazi and Elisabetta Fineschi of BioteXcel Ltd. made for a very productive two-day conference with many key leaders in the field from across the UK.  Participants agreed that … Continue reading






Posted in genomics, Oncology, personalized medicine, Uncategorized | Tagged , , , , | Comments Off on Circulating Biomarkers Dundee 2014 a Success!

Was the FDA Right to Shut Down 23andMe’s Marketing?

My opinion: the FDA was right to act in November by asking 23andMe to stop marketing  its personal genome service.  Now, don’t get me wrong, I have been rooting for 23andMe to succeed at what they are doing in the … Continue reading






Posted in DTC Genetic Testing, genomics, personalized medicine | Tagged , , , , , , | Comments Off on Was the FDA Right to Shut Down 23andMe’s Marketing?

FDA Tells 23andMe to Stop Marketing: Death Knell for DTC Genomics 1.0?

The FDA on Friday published a letter  addressed to 23andMe’s CEO, Anne Wojcicki, telling the company to cease marketing it’s Saliva Collection Kit and Personal Genome Service (PGS). In the letter, Alberto Gutierrez, Director of the Office of In vitro … Continue reading






Posted in DTC Genetic Testing, genomics, personalized medicine, Uncategorized | Tagged , , , , , | Comments Off on FDA Tells 23andMe to Stop Marketing: Death Knell for DTC Genomics 1.0?

Where are we with Targeted Cancer Therapeutics?

In a recent project, I received a draft manuscript discussing targeted cancer therapeutics and companion diagnostics in which the writer made this statement: ”CML patients in treatment with Gleevec now have the same life expectancy as people without the disease, … Continue reading






Posted in Oncology, personalized medicine | Tagged , , , , | Comments Off on Where are we with Targeted Cancer Therapeutics?

Gene Patents No More

As most of you know at this point, on Jun 13, 2013 the Supreme Court of the United States ruled essentially that native DNA sequences are not patentable subject matter.  The question ended up with the Supreme Court precisely because … Continue reading






Posted in genomics, personalized medicine | Tagged , , , , , | Comments Off on Gene Patents No More

DTC Genomics: Opportunity Lost?

Once I warmed up to the idea of startup companies offering to sequence the DNA of anyone capable of ordering from Amazon.com, I began to look forward to what might come of this nascent industry. Enabling individuals to have their … Continue reading






Posted in DTC Genetic Testing, genomics, personalized medicine | Tagged , , , , , | Comments Off on DTC Genomics: Opportunity Lost?

Time to Rethink Cancer Therapy?

In an earlier post, I wondered a bit about the ultimately causes of cancer.  For the last several decades cancer has been labeled as a genetic disease, an idea which we have chased with great fervor.  Yet, It feels to … Continue reading






Posted in genomics, Oncology, personalized medicine | Tagged , , , , | Comments Off on Time to Rethink Cancer Therapy?

DTC Genomics Update

I have fallen a bit behind in posts about the DTC genomics field.  One change in my posts to note with respect to this subject, I am going to start using the term “personal genomics” to describe the field, since … Continue reading






Posted in DTC Genetic Testing, genomics, personalized medicine | Tagged , , , , | Comments Off on DTC Genomics Update

DTC Genomics Profitable?

Maybe there is hope that 23andMe, as well as the other DTC genomics companies can make a living in the end: http://www.bio-itworld.com/els/2012/05/29/23andme-announces-first-patent.html Although, it is not clear how useful this particular patent will be.  More detailed discussion here: http://www.genomicslawreport.com/index.php/2012/06/01/patenting-and-personal-genomics-23andme-receives-its-first-patent-and-plenty-of-questions/






Posted in DTC Genetic Testing, genomics, personalized medicine | Tagged , , | Comments Off on DTC Genomics Profitable?

Lessons learned from tumor heterogeneity

My recent blog post, Tumor heterogeneity, revealed…, discussed the New England Journal of Medicine article by Gerlinger and colleagues describing the genetic heterogeneity found both within a patient’s individual tumor nodules and between spatially separate nodules.  There has been a … Continue reading






Posted in genomics, Oncology, personalized medicine, Uncategorized | Tagged , , , , , | Comments Off on Lessons learned from tumor heterogeneity